Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17536013 | 0.73 | CHRM2 (0.39) | NR1H2GPR119ESR2BUB1USP2 | |
| SCHEMBL17536005 | 0.73 | BUB1 (0.39) | CTSKNR1H2ESR2BUB1USP2 | |
| SCHEMBL626936 | 0.71 | ESR2 (0.49) | CTSKNR1H2GPR119ESR2USP2 | |
| SCHEMBL2493397 | 0.70 | NR1H2 (0.41) | CTSKNR1H2GPR119ESR2USP2 | |
| SCHEMBL23537542 | 0.69 | NR1H2 (0.35) | CTSKNR1H2ESR2BUB1USP2 | |
| SCHEMBL23537540 | 0.69 | NR1H2 (0.35) | CTSKNR1H2ESR2BUB1USP2 | |
| SCHEMBL7415947 | 0.67 | NR1H2 (0.50) | CTSKNR1H2GPR119ESR2USP2 | |
| SCHEMBL7018328 | 0.67 | CTSK (0.36) | CTSKNR1H2GPR119BUB1MEN1 | |
| SCHEMBL26884952 | 0.66 | USP2 (0.42) | CTSKNR1H2BUB1USP2SMN1; SMN2 | |
| SCHEMBL31079055 | 0.66 | CTSK (0.44) | CTSKGPR119USP2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266987-B1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-05-17 | — | — | EP | disclosed |
| EP-1575954-B1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-03 | — | — | EP | disclosed |
| US-8785448-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-22 | — | — | US | disclosed |
| US-20130344031-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-26 | — | — | US | disclosed |
| US-8557845-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-8557857-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-8481585-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-07-09 | — | — | US | disclosed |
| US-20130017170-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| US-20130012507-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-10 | — | — | US | disclosed |
| US-20090082346-A1 | Substituted Pyrrolo-Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-03-26 | — | — | US | disclosed |
| US-7407971-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2008-08-05 | — | — | US | disclosed |
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | CCNI, CDK1, CDK2 | CTSK 1511/4885NR1H2 3726/4885GPR119 2252/4885 |
| US-20130344031-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | CTSK 1511/4885NR1H2 3726/4885GPR119 2252/4885 |
| US-20130012507-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | CTSK 1511/4885NR1H2 3726/4885GPR119 2252/4885 |
| US-20090082346-A1 | Substituted Pyrrolo-Pyrazole Derivatives as Kinase Inhibitors | CCNI, CDK1, CDK2 | CTSK 1511/4885NR1H2 3726/4885GPR119 2252/4885 |
| US-20130017170-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | CTSK 1511/4885NR1H2 3726/4885GPR119 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.